Microcap Ledger Larimar Therapeutics, Inc. $LRMR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Bala Cynwyd, PA
- Fiscal year end
- December 31
- Shares outstanding
- 103,882,937 [10-Q 2026-08-04]
What the company doesAI summary of filing
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare diseases using its cell penetrating peptide technology platform. The company's lead product candidate, nomlabofusp, is an investigational subcutaneously administered fusion protein designed to deliver the protein frataxin to patients with Friedreich's ataxia, a rare progressive genetic disease. The company has completed Phase 1 and Phase 2 clinical trials in adults and a Phase 1 pharmacokinetic study in adolescents, and is currently conducting an ongoing open-label study. Larimar is pre-revenue and has no commercial products; as of December 31, 2025, the company had $136.9 million in cash and cash equivalents, which together with $107.6 million raised in a February 2026 public offering is expected to fund operations into the second quarter of 2027. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$62.40M | −$88.64M | $92.69M | [10-Q 2026-08-04] |
| FY ended Dec 2025 | — | −$165.67M | −$113.20M | $85.41M | [DEF 14A 2026-04-20] |
| FY ended Dec 2024 | — | −$80.60M | −$70.76M | $33.22M | [DEF 14A 2026-04-20] |
- Quarterly cash burn
- −$44.32M
- Cash runway Estimate
- ~6.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 63,806,628 | [10-Q 2024-10-30] |
| 2025-03-20 | 64,027,892 | [10-K 2025-03-24] |
| 2025-04-27 | 64,027,892 | [10-Q 2025-04-30] |
| 2025-08-12 | 85,590,392 | [10-Q 2025-08-14] |
| 2025-11-03 | 85,590,392 | [10-Q 2025-11-05] |
| 2026-03-17 | 103,882,937 | [10-K 2026-03-19] |
| 2026-05-12 | 103,882,937 | [10-Q 2026-05-14] |
| 2026-08-02 | 103,882,937 | [10-Q 2026-08-04] |
- Shelf registration
- S-3 filed 2024-05-09; declared effective 2024-05-24 [S-3 2024-05-09]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-29 | Harlow John B. Jr. | grant | 50,000 | — | [4 2026-10-01] |
| 2026-07-06 | Hamilton Thomas Edward | buy | 50,000 | $3.34 | [4 2026-07-08] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Director or officer change |
| 2026-08-04 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Results of operations; Other events |
| 2026-06-29 | 8-K | Other events |
| 2026-05-19 | 8-K | Shareholder vote results |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-14 | 8-K | Results of operations; Other events |
| 2026-04-30 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-20 | DEF 14A | Proxy statement |
| 2026-04-10 | PRE 14A | Proxy statement |
| 2026-03-19 | 10-K | Annual report |
Alerts for $LRMR
Email me when Larimar Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.